19 hrs ago
STTG Market Recap March 14, 2014
Stocks finished off a rough week with mild losses; the S&P 500 gave back 0.28% and the NASDAQ 0.35%.
Trending on the Topix Network
CytoDyn Inc: New Hope for HIV
Daphne Joseph, a registered nurse with more than two decades experience dealing with AIDS and other STIs, discusses some misconceptions about how the HIV/AIDS can be transmitted.
Gilead Sciences CEO cashes in . . . again
Your Take contributions have not been reviewed for accuracy by USA TODAY. Contributors agree to our Terms of Service and are responsible for the content of their videos and photos.
Celgene, Gilead and a Truckload of Patent Trouble
Shares of Gilead and Celgene have tumbled today after both companies revealed that they were facing patent pressures.
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences
Idenix Pharmaceuticals has filed patent infringement lawsuits against Gilead Sciences and/or certain of its subsidiaries in each of three countries - France, Germany and the United Kingdom.
Gilead sees vast India market for hepatitis C drug
Sovaldi, the highly-touted new hepatitis C drug developed by Gilead Sciences, could be available to patients in India within two years.
Thu Mar 13, 2014
4 Health Care Stocks With More Than 100% Upside
In a bull market that has propped up a wide range of sectors and industries, few have benefited as much as biotech stocks.
Global elvitegravir market: New market research published
Forecast and Market Analysis to 2022". Human Immunodeficiency Virus , the causative agent of AIDS, has claimed millions of lives since its emergence.
Wed Mar 12, 2014
New Hampshire Public Radio -
Healthier Patients May Have To Wait For Costly Hepatitis C Drugs
Expensive new drugs for hepatitis C may work better than older treatments, but their high cost undermines their value, a panel of experts said Monday during a daylong forum in San Francisco Monday.
Tue Mar 11, 2014
New hepatitis C drug - worth $1,000 a pill?
THE NATIONAL WEATHER SERVICE HAS ISSUED A WINTER STORM WARNING FOR HEAVY SNOW...BLOWING SNOW...WHICH IS IN EFFECT FROM 5 AM WEDNESDAY TO 5 AM EDT THURSDAY.
Gilead Sciences' Novel Leukemia Drug Should Extend Company Profits
Gilead Sciences has gained most of its fame as an antiviral drug maker, developing and selling a number of quality HIV and hepatitis medicines.
Gilead's breakthrough hepatitis C drug is too expensive, medical experts say
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences.
National Public Radio
Medical Groups Question Price Of New Hep C Drug
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences.
Mon Mar 10, 2014
Evidence For And Against A Biotech Bubble
While superficial evidence of a bubble exists, I believe a deeper look at the issue reveals that such talk is premature.
Sat Mar 08, 2014
Gilead's Combo Therapy Cures Hep C in Just Six Weeks
Just six weeks of Gilead Sciences' hotly anticipated combination pill of ledipasvir and Sovaldi , given with or without GS-9669 or GS-9451, cured 95 to 100 percent of people with genotype 1 of hepatitis C virus in a small pilot study, MedPage Today reports.
Fri Mar 07, 2014
Today's Market: Biotech & Technology Stocks, Time To Worry?
During bull markets there are always those individuals who try to time tops, just as there are always individuals who try to call the bottoms in bear markets.
Stocks with implied volatility movement; Gild Celg
Gilead weakness a buying opportunity, says Stifel Stifel sees the weakness in Gilead which was caused by Merck's announcement of a competitive drug, as a buying opportunity.
Biotech Bust: 5 Drivers
What the heck happened to the biotechnology sector on Thursday ? It's continuing on Friday, with Gilead Sciences and iShares Nasdaq Biotechnology Index ETF down by 2% and 1.3%, respectively.
Stocks erase gains after February jobs surprise
After gaining ground in early trading, the Dow and S&P 500 were flat while the Nasdaq was in the red.
Investor-Edge.com Most Active Equities Watch List: Staples, Gilead Sciences, Office Depot, and Sprint
The S&P 500 finished the session 0.17% higher at 1,877.03. The gains were broad based with 7 of 10 sectors going up.